UnitedHealth rises 3.0% as healthcare sector rallies after Optum partnership news

What happened

UnitedHealth (UNH) rose 3.0% on October 20, 2026, as the healthcare sector rallied after Optum announced a partnership with Syneos Health. The stock closed at $419.26 on trading volume that was 1.2 times its 20-day average, while the healthcare sector median rose 3.0% and the S&P 500 rose 0.3%. With a market value of $360.32 billion, the move largely tracked a sector-wide advance rather than company-specific news.

How big was the move

The day’s gain was 2.0 times a typical daily move for the stock and was 0.1 percentage points better than the sector median. Over the last five sessions the stock rose 11.0% while the S&P 500 over five sessions fell 1.2%. Its market sensitivity is a beta of 0.42, which indicates the stock tended to move less than the market. In the past five years the stock had 41 sessions with a gain of at least 3.0%; twenty trading days later the median result was a gain of 1.3%, and 22 of 41 were higher.

The technical picture

The stock closed 9.7% above its 20-day moving average and 8.2% above its 50-day moving average, and it was 16.5% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock had been above the 200-day average for 133 consecutive trading days. The Relative Strength Index (14 days) was 71, above 70, a level often called overbought, and the stock was 9.2% below the 52-week high.

Over one month the stock rose 11.0% but over three months it fell 2.8%. Over one year it rose 17.6%, which was 1.8 percentage points ahead of the S&P 500. Volatility was 24% annualized over 60 days, lower than 62% of its own readings over five years, suggesting recent moves have been steadier than many prior episodes.

Fundamentals and valuation

For the four quarters through September 30, 2026, revenue was $449.66 billion, which grew 3.3% from a year earlier. Diluted earnings per share were $17.52, with earnings per share growth from a year earlier that fell 8.6%. Gross margin was 22.8% (a year earlier: 19.7%), while operating margin was 5.3% (a year earlier: 6.1%). Free-cash-flow margin was 5.1%, return on invested capital was 10.0%, and the balance sheet showed net debt of 1.7 times EBITDA. Share count over one year decreased by 1.1%.

The stock traded at 23.9 times trailing earnings and 20.6 times expected earnings, with a free-cash-flow yield of 6.3%. Its price to trailing earnings was lower than 52% of its own readings over the past five years (five-year median: 26.3 times earnings). PromtFinance scores ranked the company highly on Value at 91 (Exceptional) and Stability at 83 (Strong), while Growth scored 37 (Weak), suggesting a mix of attractive income metrics and slower sales expansion.

Earnings and analyst expectations

UnitedHealth last reported on October 13, 2026, with earnings per share of $4.69 against $4.14 expected, 13.3% above estimates. The company had beaten estimates for five consecutive quarters, and the average surprise over the last four reports was 13.4% above estimates. Typical two-day reactions after recent reports showed the stock fell 5.9%.

Analysts’ consensus price target was $471.33, which was 12.4% above the closing price. Fifty-two analysts had ratings on the stock, with 83% rating the stock Buy and a consensus rating of Buy. The contrast between a valuation at 23.9 times trailing earnings and a free-cash-flow yield of 6.3% framed the stock as fairly valued by some metrics while still offering cash generation that may support the current rating.

What to watch

• Jan. 26, 2027: next scheduled earnings report date
• Oct. 20, 2026: Optum announced a partnership with Syneos Health, according to GlobeNewsWire
• The stock’s Relative Strength Index (14 days) at 71
• Price to trailing earnings at 23.9 times and free-cash-flow yield at 6.3%